CD274 and non-small cell lung carcinoma: The phase II Lung Cancer Mutation Consortium 3 (LCMC3) study was performed to evaluate the efficacy of neoadjuvant atezolizumab, a PD-L1 inhibitor, in a large population of treatment-naive patients with resectable, stage IB–IIIB NSCLC.